Video

Vandetanib Advantages in Medullary Thyroid Cancer

Author(s):

Peter Langmuir, MD

Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Related Content
Jared Weiss, MD, an associate professor of medicine in the Division of Oncology, Department of Medicine at the University of North Carolina (UNC) School of Medicine, as well as an associate director of finance in the UNC Lineberger Clinical Protocol Office at the UNC Lineberger Comprehensive Cancer Center
October 3rd 2024

First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Ruihua Xu, MD, PhD, of Sun Yat-sen University Cancer Center
September 25th 2024

Toripalimab Plus Chemo Wins European Approval for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
September 2nd 2021

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

Elizabeth J. Franzmann, MD, FACS, of Sylvester Comprehensive Cancer Center
September 9th 2024

Oral Rinse-Based Test Demonstrates Ability to Detect Recurrence of Head and Neck Cancer

FDA
August 23rd 2024

FDA Grants Fast Track Designation to Neoadjuvant APG-157 for Head and Neck Cancer